Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Ian N Bruce; Sarowar Golam; Jason Steenkamp; Pearl Wang; Evelyn Worthington; Barnabas Desta; Konstantina Psachoulia; Wilma Erhardt; Raj Tummala

doi:10.2217/cer-2022-0192

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

J Comp Eff Res. 2023 Jan;12(1):e220192. doi: 10.2217/cer-2022-0192. Epub 2022 Dec 14.

Authors

Ian N Bruce¹, Sarowar Golam², Jason Steenkamp³, Pearl Wang³, Evelyn Worthington³, Barnabas Desta⁴, Konstantina Psachoulia⁵, Wilma Erhardt², Raj Tummala⁵

Affiliations

¹ Division of Musculoskeletal & Dermatological Sciences, Centre for Epidemiology Versus Arthritis, The University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
² Global Market Access & Pricing, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
³ EVERSANA™, Burlington, ON, L7N 3H8, Canada.
⁴ BioPharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD 20878, USA.
⁵ Respiratory, Inflammation & Autoimmunity, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

No abstract available

Keywords: comparative effectiveness research; indirect treatment comparison; randomized controlled trials; simulated treatment comparison; systemic lupus erythematosus.

Publication types

Research Support, Non-U.S. Gov't
Letter
Comment

MeSH terms

Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized* / therapeutic use
Humans
Lupus Erythematosus, Systemic* / drug therapy
Treatment Outcome

Substances

anifrolumab
belimumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal